Free Trial

Anika Therapeutics (ANIK) News Today

Anika Therapeutics logo
$17.25 +0.25 (+1.47%)
(As of 11/15/2024 ET)
Anika Therapeutics (NASDAQ:ANIK) Cut to Hold at StockNews.com
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
Anika Therapeutics, Inc. stock logo
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA
Capital Management Corp VA trimmed its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 11.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,350 shares of th
Anika Therapeutics, Inc. stock logo
Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com
StockNews.com downgraded Anika Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.
Anika Therapeutics price target lowered to $25 from $37 at Barrington
Anika (ANIK) Earnings Dates & Reports
Anika Therapeutics, Inc. stock logo
Barrington Research Issues Pessimistic Forecast for Anika Therapeutics (NASDAQ:ANIK) Stock Price
Barrington Research dropped their price objective on Anika Therapeutics from $37.00 to $25.00 and set an "outperform" rating for the company in a report on Friday.
Anika Reports Third Quarter 2024 Financial Results
Anika Therapeutics, Inc. stock logo
Anika Therapeutics, Inc. (NASDAQ:ANIK) Sees Significant Decline in Short Interest
Anika Therapeutics, Inc. (NASDAQ:ANIK - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 489,100 shares, a drop of 23.5% from the September 30th total of 639,300 shares. Currently, 3.4% of the company's stock are sold short. Based on an average trading volume of 49,200 shares, the short-interest ratio is presently 9.9 days.
Anika Therapeutics, Inc. stock logo
Riverwater Partners LLC Has $2.55 Million Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK)
Riverwater Partners LLC raised its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 539.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,996 shares of the biotechnology company's stock after acquiri
Anika Therapeutics, Inc. stock logo
Anika Therapeutics (ANIK) Set to Announce Earnings on Thursday
Anika Therapeutics (NASDAQ:ANIK) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636929)
Anika Therapeutics, Inc. stock logo
Anika Therapeutics (NASDAQ:ANIK) Rating Reiterated by Barrington Research
Barrington Research reaffirmed an "outperform" rating and set a $37.00 price target on shares of Anika Therapeutics in a research note on Tuesday.
Anika Therapeutics, Inc. stock logo
Short Interest in Anika Therapeutics, Inc. (NASDAQ:ANIK) Drops By 5.0%
Anika Therapeutics, Inc. (NASDAQ:ANIK - Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 639,300 shares, a decline of 5.0% from the September 15th total of 673,300 shares. Based on an average daily trading volume, of 50,200 shares, the days-to-cover ratio is currently 12.7 days. Currently, 4.5% of the shares of the company are short sold.
Anika Therapeutics, Inc. stock logo
Squarepoint Ops LLC Sells 30,809 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)
Squarepoint Ops LLC decreased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 58.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,648 shares of the biotechnology company's stock after selling
Anika Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Sells 60,471 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)
Dimensional Fund Advisors LP trimmed its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 7.5% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 749,284 shares of the biotechnology company's stock after selling 60,471 sh
Anika Therapeutics, Inc. stock logo
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Stonepine Capital Management LLC
Stonepine Capital Management LLC increased its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 171.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 165,397 shares of the biotechnology company's stock after acqu
Anika Therapeutics, Inc. stock logo
Meros Investment Management LP Acquires 42,587 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)
Meros Investment Management LP lifted its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 25.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,714 share
Anika Therapeutics, Inc. stock logo
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC increased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 6.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 598,229 shares of the biotechnology company's stock after p
Anika Therapeutics, Inc. stock logo
Acadian Asset Management LLC Purchases 21,517 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)
Acadian Asset Management LLC grew its position in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 5.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 442,944 shares of the biotechnology company's stock after buying an additional 21,517 shares during
Anika Therapeutics, Inc. stock logo
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200-Day Moving Average of $25.90
Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above 200 Day Moving Average of $25.90
Get Anika Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

The only candlestick pattern worth a darn (Ad)

It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…

Follow this link here and enter your email address to sign up…

ANIK Media Mentions By Week

ANIK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANIK
News Sentiment

0.44

0.56

Average
Medical
News Sentiment

ANIK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANIK Articles
This Week

1

2

ANIK Articles
Average Week

Get Anika Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ANIK) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners